Kurt Samuel Schultz

Dr. Kurt Samuel Schultz

Surgery, Yale School of Medicine, New Haven, Connecticut, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
EFEmily Flom
Emily Flom
Kurt Samuel SchultzKurt Samuel Schultz
Kurt Samuel Schultz
HPHaddon J. Pantel
Haddon J. Pantel
ILIra L. Leeds
Ira L. Leeds
The modern rectal cancer treatment paradigm offers additional opportunities for organ preservation, most notably via total neoadjuvant therapy (TNT) and consideration for a watch-and-wait (WW) surveillance-only approach. A major barrier to widespread implementation of a WW approach to rectal cancer is the potential discordance between a clinical complete response (cCR) and a pathologic complete response (pCR). In the pre-TNT era, the identification of predictors of pCR after neoadjuvant therapy had been previously studied. However, the last meta-analysis to assess the summative evidence on this important treatment decision point predates the acceptance and dissemination of TNT strategies. The purpose of this systematic review was to assess preoperative predictors of pCR after TNT to guide the ideal selection criteria for WW in the current era. An exhaustive literature review was performed and the electronic databases Embase, Ovid, MEDLINE, PubMed, and Cochrane were comprehensively searched up to 27 June 2023. Search terms and their combinations included “rectal neoplasms”, “total neoadjuvant therapy”, and “pathologic complete response”. Only studies in English were included. Randomized clinical trials or prospective/retrospective cohort studies of patients with clinical stage 2 or 3 rectal adenocarcinoma who underwent at least 8 weeks of neoadjuvant chemotherapy in addition to chemoradiotherapy with pCR as a measured study outcome were included. In this systematic review, nine studies were reviewed for characteristics positively or negatively associated with pCR or tumor response after TNT. The results were qualitatively grouped into four categories: (1) biochemical factors; (2) clinical factors; (3) patient demographics; and (4) treatment sequence for TNT. The heterogeneity of studies precluded meta-analysis. The level of evidence was low to very low. There is minimal data to support any clinicopathologic factors that either have a negative or positive relationship to pCR and tumor response after TNT. Additional data from long-term trials using TNT is critical to better inform those considering WW approaches following a cCR.

1 March 2021 in Journal of Surgical Education
Verified
Journal Article
Closed access
Kurt Samuel SchultzKurt Samuel Schultz
Kurt Samuel Schultz
DHDonald T. Hess
Donald T. Hess
TSTeviah E. Sachs
Teviah E. Sachs
JTJennifer F. Tseng
Jennifer F. Tseng
LPLuise I.M. Pernar
Luise I.M. Pernar

1 January 2021 in The American Journal of Surgery
Verified
Journal Article
Closed access
Kurt Samuel SchultzKurt Samuel Schultz
Kurt Samuel Schultz
SGSusanna W.L. de Geus
Susanna W.L. de Geus
TSTeviah E. Sachs
Teviah E. Sachs
RMRyan B. Morgan
Ryan B. Morgan
SNSing Chau Ng
Sing Chau Ng
JTJennifer F. Tseng
Jennifer F. Tseng

17 September 2025 in Surgery
Verified
Journal Article
Closed access
Kurt Samuel SchultzKurt Samuel Schultz
Kurt Samuel Schultz
MMMiranda S. Moore
Miranda S. Moore
EPEmily Y. Park
Emily Y. Park
JMJulianna M. Mastrorilli
Julianna M. Mastrorilli
ESEric B. Schneider
Eric B. Schneider
ILIra L. Leeds
Ira L. Leeds

25 October 2024 in Journal of Global Health
Verified
Journal Article
Open access
MCMadeleine Carroll
Madeleine Carroll
NRNensi Ruzgar
Nensi Ruzgar
MFMaíra Fedatto
Maíra Fedatto
Kurt Samuel SchultzKurt Samuel Schultz
Kurt Samuel Schultz
MCMaija Cheung
Maija Cheung
Historically, the US has played a key role in providing financial and technical assistance to support health initiatives and programmes around the world. As the largest contributor to development assistance for health (DAH), it has channelled substantial funding and resources to improve and maintain global health. Over the last several decades, the US allocation of […]

25 June 2025 in Cancer
Verified
Journal Article
Closed access
Kurt Samuel SchultzKurt Samuel Schultz
Kurt Samuel Schultz
VBVarun Bansal
Varun Bansal
MWMichael M. Wach
Michael M. Wach
NBNeal Bhutiani
Neal Bhutiani
FGFrederick A. Godley
Frederick A. Godley
PGPeritoneal Surface Malignancies Consortium Group
Peritoneal Surface Malignancies Consortium Group